Som et resultat af den forud planlagte interimanalyse blev dexametason- gruppen standset på anbefaling fra datamonitoreringskomiteen og fik derefter tilbudt VELCADE uanset sygdommens status.
As a result of a preplanned interim analysis, the dexamethasone arm was halted at the recommendation of the data monitoring committee and all patients randomised to dexamethasone were then offered VELCADE, regardless of disease status.